The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.
Jean W LiewTimothy TreuYojin ParkJacqueline M FergusonMorgan A RosserYuk-Lam HoDavid R GagnonRachael StovallPaul MonachSusan R HeckbertLianne S GenslerKatherine P LiaoMaureen DubreuilPublished in: Seminars in arthritis and rheumatism (2024)
In this r-axSpA cohort identified using phenotyping methods, TNFi use versus non-use had a lower risk of incident CVD. These findings provide reassurance regarding the CV safety of TNFi agents for r-axSpA treatment. Replication of these results in other cohorts is needed.